Abid Mushtaq, Saba Zartash, Muhammad Javed, M Asim Rana, M A Qayyum, T Bibi, M M Ullah Saif, M M Hafeez
Aim: To evaluate the effectiveness of Ivermectin in COVID 19 infection in terms of virus clearance and symptomatic improvement. Study design: Prospective Quasi experimental study Place and duration of study: Study was carried out in COVID treatment units of Services Institute of Medical Sciences and Bahria International Hospital COVID treatment centre from April 15, 2020 to November 30, 2020 Methodology: One hundred COVID19 confirmed patients for this study and divided into 2 groups. Both groups were given standard treatment including Oxygen, therapeutic anticoagulation and hydroxychloroquine therapies. Group-1 was given Ivermectin for 6 days and group 2 didn’t receive Ivermectin.
Results: The significance value represented as p value (p=.825) was greater than the table value at 0.05 in all aspects, which shows that Ivermectin has no effect in improving PF ratio in COVID19 patients. Out of 50 only 4 patients who received Ivermectin got COVID19 PCR negative after 6 days but on the other hand 3 patients who did not receive Ivermectin also got their PCR negative after 6 days of treatment. Conclusion: Ivermectin does not seem to be effective in improvement of PF ratio and virus clearance in COVID19 patients. Keywords: SARS-CoV-2, COVID-19, PF ratio, Ivermectin, Virus clearance, Anti-viral treatment, Viral clearance